Ofatumumab in advanced stage chronic lymphocytic leukaemia: Results of the UK named patient compassionate use programme

British Journal of Haematology

Volumn 155, Issue 4, 2011, Pages 519-521

  Chowdhury, Onima ^a   Varghese, Abraham ^b   Pattinson, Jonathon ^c   Carrington, P ^d   Bloor, Adrian ^e   Follows, George A ^f   Hillmen, Peter ^b   Schuh, Anna ^g  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c BUCKINGHAMSHIRE HEALTHCARE NHS TRUST   (United Kingdom)

^d TRAFFORD GENERAL HOSPITAL   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chemotherapy; Chronic lymphocytic leukaemia; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; OFATUMUMAB;

ADULT; ADVANCED CANCER; AGED; BASAL CELL CARCINOMA; CANCER CONTROL; CANCER STAGING; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; CYTOPENIA; DRUG INFUSION; HEALTH PROGRAM; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LETTER; LEUKEMIA REMISSION; MELANOMA; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RESPIRATORY TRACT INFECTION; TREATMENT RESPONSE; TRISOMY 12; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COMPASSIONATE USE TRIALS; FEMALE; GREAT BRITAIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 80054996610     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08711.x     Document Type: Letter

References (5)

1. Cheson, B.D. (2010) Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Journal of Clinical Oncology, 28, 3525-3530.
2. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
3. Tracy, J.A. & Dyck, P.J. (2010) Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies. Current opinion in neurology, 23, 242.
4. Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmann, A., Robak, T., Furman, R.R., Hillmen, P. & Trneny, M. (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1749.
5. Zenz, T., Volden, M., Mast, T., Kinzer, N., Winkler, D., Schnaiter, A., Bühler, A., Engelberts, P., Bakker, J., Beurskens, F., Parren, P., Döhner, H. & Stilgenbauer, S. (2010) In vitro activity of the CD20 antibody Ofatumumab in genetic high risk CLL with TP53 mutation/deletion. Haematologica, 95(Suppl. 2), 328, abstract 0786.